Shares of Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $27.75.
Several equities research analysts have weighed in on the company. Wedbush assumed coverage on Cullinan Oncology in a report on Thursday, February 15th. They issued an “outperform” rating and a $30.00 target price for the company. HC Wainwright lowered their target price on Cullinan Oncology from $34.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday. BTIG Research boosted their price target on Cullinan Oncology from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, William Blair assumed coverage on Cullinan Oncology in a research report on Monday. They issued an “outperform” rating for the company.
Get Our Latest Stock Analysis on Cullinan Oncology
Cullinan Oncology Trading Up 3.2 %
Cullinan Oncology (NASDAQ:CGEM – Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.42. As a group, equities analysts anticipate that Cullinan Oncology will post -3.55 EPS for the current fiscal year.
Insider Activity at Cullinan Oncology
In related news, insider Corrine Savill sold 18,684 shares of the company’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $12.14, for a total transaction of $226,823.76. Following the transaction, the insider now directly owns 165,990 shares of the company’s stock, valued at approximately $2,015,118.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 98,684 shares of company stock valued at $1,437,624 in the last ninety days. Corporate insiders own 8.82% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new position in shares of Cullinan Oncology in the second quarter valued at about $53,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Cullinan Oncology by 352.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,954 shares of the company’s stock valued at $50,000 after purchasing an additional 3,859 shares during the period. Point72 Middle East FZE acquired a new position in shares of Cullinan Oncology in the second quarter valued at about $59,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Cullinan Oncology by 1,331.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,542 shares of the company’s stock valued at $59,000 after purchasing an additional 6,085 shares during the period. Finally, Royal Bank of Canada increased its holdings in shares of Cullinan Oncology by 499.8% in the second quarter. Royal Bank of Canada now owns 8,991 shares of the company’s stock valued at $97,000 after purchasing an additional 7,492 shares during the period. 86.31% of the stock is owned by institutional investors and hedge funds.
About Cullinan Oncology
Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Further Reading
- Five stocks we like better than Cullinan Oncology
- What is an Earnings Surprise?
- United Airlines Soars on Earnings Beat
- CD Calculator: Certificate of Deposit Calculator
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Compound Interest and Why It Matters When Investing
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.